Lifecare ASA Annual Report 2024

28 Mar 2025 07:00 CET

Bergen, Norway, 28 March -- Lifecare ASA (LIFE), a medical sensor company
advancing product development for the next-generation Continuous Glucose
Monitoring (CGM), has today published its 2024 Annual Report.

Lifecare ASA has today released its 2024 Annual Report, providing insights
into Lifecare's business strategy, key milestones, and next steps toward
obtaining CE certification for its glucose sensor for use in the human
market.

2024 has been a transformative year for Lifecare, marked by significant
advancements in technology, strategic development, and market readiness. The
company has made substantial progress in developing its glucose sensor,
scaling up for large-scale manufacturing, strengthening its organization, and
moving closer to commercialization.

Lifecare is entering a pivotal phase in 2025, maintaining strong momentum in
product development and preparing for commercialization. Lifecare's continuous
glucose monitoring technology continues to advance, supported by strategic
partnerships, optimized production processes, and improvements in sensor
sensitivity. Lifecare anticipates finalizing the design of the Sencell implant
in the first half of 2025, ensuring it is optimized for manufacturing. At the
same time, Lifecare is preparing for the regulatory study to support the CE
mark application for Sencell in the human market. This study is expected to
start late 2025, with the main part taking place in 2026, targeting CE
approval and market launch by 2027.

The Annual Report is published in both the European Single Electronic Format
(ESEF) and as an PDF.
Additionally, Lifecare has published its 2024 Remuneration Report in
accordance with the Norwegian Public Limited Liability Companies Act, section
6-16b (2).
The reports are available on Lifecare's website:
https://lifecare.no/investor/reports-presentations/.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's main focus is to bring the
next generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2025-03-28 07:00 CET.

More information:
Access the news on Oslo Bors NewsWeb site

642456_lifecare-2024-12-31-0-en.zip
642456_Lifecare Annual Report 2024.pdf